Donelli M G, Vecchi A, Bossi A, Colombo T, Sironi M, Pantarotto C, Garattini S, Spreafico F
Tumori. 1977 Mar-Apr;63(2):137-46. doi: 10.1177/030089167706300203.
The interaction between cyclophosphamide (CPA) and phenobarbital (PB) was investigated in B6D2F1 mice, checking both the antileukemic and immunosuppressive activity together with the serum levels of CPA and its metabolites. A reduced cytotoxic activity of CPA has been observed when PB is given for 2 days before CPA and an interval of at least 6 hours elapses between the last treatment of PB and the administration of CPA. On the contrary, when PB is given simultaneously with CPA for 2 or 4 consecutive days, an increased antileukemic activity of CPA occurs. In the experimental condition where PB decreases the activity of CPA, serum levels of CPA, assayed by means of a new specific gas-chromatographic method, and of its NBP-alkylating metabolites, indicate that this effect may be explained on a pure pharmacokinetic basis. However, for the situation where an increased effect of CPA was observed under the influence of PB, pharmacokinetic data did not provide a clear explanation.
在B6D2F1小鼠中研究了环磷酰胺（CPA）与苯巴比妥（PB）之间的相互作用，同时检测了抗白血病和免疫抑制活性以及CPA及其代谢产物的血清水平。当在CPA给药前2天给予PB且在最后一次PB治疗与CPA给药之间间隔至少6小时时，观察到CPA的细胞毒性活性降低。相反，当PB与CPA连续2天或4天同时给药时，CPA的抗白血病活性增加。在PB降低CPA活性的实验条件下，通过一种新的特异性气相色谱法测定的CPA血清水平及其NBP-烷基化代谢产物表明，这种效应可能纯粹基于药代动力学来解释。然而，对于在PB影响下观察到CPA作用增强的情况，药代动力学数据并未提供明确的解释。
